|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 5:** Results of meta-analysis of prevalence in pregnant COVID-19 patients | | | | | | | | | | |
| **Variable** | **Numbers of studies** | **Patients** | **Total patients** | **Crude Prevalence [%]** | **Random effect model (REM) Prevalence\*** | **REM (lower CI)** | **REM (upper CI)** | **Tau** | **I 2** | **Q** |
| **Comorbidities** |  |  |  |  |  |  |  |  |  |  |
| Any comorbidity | 2 | 2 | 10 | 20 | 20 | 5.04 | 54.07 | 0 | 0 | 3.73 |
| Hypothyroidism | 1 | 1 | 1 | 100 |  |  |  |  |  |  |
| Influenza | 1 | 1 | 9 | 11.11 |  |  |  |  |  |  |
| Allergies | 1 | 1 | 1 | 100 |  |  |  |  |  |  |
| **Signs and symptoms** |  |  |  |  |  |  |  |  |  |  |
| Fever | 10 | 25 | 35 | 71.43 | 96.35 | 17.57 | 99.97 | 7.628 | 81.5 | 19.95 |
| Cough | 6 | 12 | 29 | 41.38 | 41.38 | 25.21 | 59.64 | 0 | 0 | 5.8 |
| Fatigue | 3 | 5 | 18 | 27.78 | 58.94 | 1.45 | 99.29 | 2.893 | 64.1 | 5.83 |
| Diarrhea | 3 | 32 | 26 | 123.08 | 10.45 | 0.19 | 87.7 | 8.865 | 82.8 | 7.82 |
| Sore throat | 1 | 2 | 9 | 22.22 |  |  |  |  |  |  |
| Chest tightness | 1 | 1 | 9 | 11.11 |  |  |  |  |  |  |
| Myalgia | 1 | 3 | 9 | 33.33 |  |  |  |  |  |  |
| Dyspnea | 2 | 3 | 19 | 15.79 | 15.79 | 5.18 | 39.15 | 0 | 0 | 0.7 |
| Nasal congestion | 1 | 1 | 1 | 100 |  |  |  |  |  |  |
| Dizziness or confusion | 1 | 2 | 9 | 22.22 |  |  |  |  |  |  |
| **Imaging features** |  |  |  |  |  |  |  |  |  |  |
| Pathologic findings | 10 | 31 | 35 | 88.57 | 88.57 | 73.23 | 95.64 | 0 | 0 | 3.16 |
| Pneumonia | 10 | 31 | 35 | 88.57 | 88.57 | 73.23 | 95.64 | 0 | 0 | 3.16 |
| Ground glass opacity (GGO) | 9 | 29 | 34 | 85.29 | 85.29 | 69.18 | 93.74 | 0 | 0 | 4.12 |
| Bilateral pneumonia | 6 | 15 | 21 | 71.43 | 71.43 | 49.24 | 86.57 | 0 | 0 | 3.96 |
| Unilateral pneumonia | 2 | 4 | 17 | 23.53 | 23.53 | 9.12 | 48.55 | 0 | 0 | 3.11 |
| Consolidation | 1 | 8 | 16 | 50 |  |  |  |  |  |  |
| GGO with consolidation | 3 | 9 | 18 | 50 | 50 | 28.42 | 71.58 | 0 | 0 | 3.02 |
| Local patchy shadowing | 1 | 1 | 1 | 100 |  |  |  |  |  |  |
| Pleural effusion | 1 | 6 | 16 | 37.5 |  |  |  |  |  |  |
| Subpleural opacities | 2 | 2 | 2 | 100 |  |  |  |  |  |  |
| Bronchiectasis | 1 | 1 | 3 | 33.33 |  |  |  |  |  |  |
| **Treatment** |  |  |  |  |  |  |  |  |  |  |
| Antiviral treatment | 6 | 11 | 14 | 78.57 | 78.57 | 50.57 | 92.93 | 0 | 0 | 3.09 |
| Antibiotics | 6 | 14 | 14 | 100 |  |  |  |  |  |  |
| Corticosteroids | 4 | 3 | 12 | 25 | 100 | 6.32 | 100 | 25’452.2 | 100 | 13.5 |
| High flow nasal cannula | 2 | 10 | 10 | 100 |  |  |  |  |  |  |
| Alpha-interferon aerosol inhalation | 2 | 2 | 2 | 100 |  |  |  |  |  |  |
| Lopinavir | 2 | 2 | 2 | 100 |  |  |  |  |  |  |
| Ritonavir | 2 | 2 | 2 | 100 |  |  |  |  |  |  |
| Oxygen therapy | 4 | 3 | 12 | 25 | 100 | 6.32 | 100 | 25’452.2 | 100 | 13.5 |
| Moxifloxacin hydrochloride | 2 | 2 | 2 | 100 |  |  |  |  |  |  |
| Piperacillin tazobactam | 1 | 1 | 1 | 100 |  |  |  |  |  |  |
| Sulbactam | 1 | 1 | 1 | 100 |  |  |  |  |  |  |
| **Outcome** |  |  |  |  |  |  |  |  |  |  |
| Death | 7 | 0 | 9 | 0 |  |  |  |  |  |  |
| Survived | 7 | 9 | 9 | 100 |  |  |  |  |  |  |
| Discharged | 4 | 4 | 6 | 66.67 | 66.67 | 26.81 | 91.61 | 0 | 0 | 3.82 |
| Recovery | 3 | 3 | 3 | 100 |  |  |  |  |  |  |
| Remained hospitalized | 3 | 1 | 3 | 33.33 | 33.33 | 1.98 | 92.51 | 0 | 0 | 3.82 |
| **Complications** |  |  |  |  |  |  |  |  |  |  |
| Admission to intensive care unit | 1 | 1 | 1 | 100 |  |  |  |  |  |  |
| \*Model does not convert if there is only one study or 100% of the patients have events. | | | | | | | | | |  |